P.R. Herzig & Co’s Teva Pharmaceuticals TEVA Stock Holding History

P.R. Herzig & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-27,100	Closed	-$1.6M	–	50
2015 Q2	$1.6M	Sell	27,100 -14,200	-34%	-$876K	3.24%	10
2015 Q1	$2.57M	Hold	41,300	–	–	4.4%	6
2014 Q4	$2.38M	Buy	41,300 +3,400	+9%	+$189K	3.67%	5
2014 Q3	$2.04M	Sell	37,900 -200	-0.5%	-$10.6K	3.02%	9
2014 Q2	$2M	Buy	38,100 +2,100	+6%	+$107K	2.64%	12
2014 Q1	$1.9M	Buy	36,000 +30,900	+606%	+$1.43M	2.49%	14
2013 Q4	$204K	Buy	+5,100	New	+$201K	0.25%	59
2013 Q3	–	Sell	-68,848	Closed	-$2.7M	–	71
2013 Q2	$2.7M	Buy	+68,848	New	+$2.68M	5.21%	3

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

P.R. Herzig & Co's TEVA Position: Q3 2015 in Review

P.R. Herzig & Co sold out of Teva Pharmaceuticals (TEVA) in Q3 2015, closing a stake of 27,100 shares — an estimated $1.6M sold.

P.R. Herzig & Co first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.7M in Q2 2013. 824 funds tracked by Wall St. Rank hold TEVA as of Q3 2015.

P.R. Herzig & Co reported no remaining Teva Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
P.R. Herzig & Co sold 27,100 Teva Pharmaceuticals shares in Q3 2015, an estimated $1.6M.
P.R. Herzig & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
P.R. Herzig & Co's Teva Pharmaceuticals position peaked at $2.7M in Q2 2013.
824 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2015.

Based on P.R. Herzig & Co's 13F filing for Q3 2015, filed 19 Oct 2015.